ELDN Eledon Pharmaceuticals: שווי הפעילות העסקית

The price action for Eledon Pharmaceuticals (ELDN) reflects an enterprise value of 175.01, driven by strict temperature control during biomaterial transport and adherence to laboratory safety standards without the use of manufacturing plants. The business relies on developing anti-organ rejection agents, focusing on blocking the CD40L pathway to minimize therapy toxicity across B2B and B2C segments.
Eledon Pharmaceuticals (ELDN) - פילוחי מדדים ודוחות פיננסיים

Enterprise value is calculated as the sum of market capitalization and net debt, reflecting the total cost of acquiring the business inclusive of all liabilities and liquid assets. For Eledon Pharmaceuticals (ELDN), the enterprise value reflects a speculative valuation currently based on clinical trial expectations for its antibody rather than current operating revenues.